As they matured from prenatal to adult, heart cells reduced the number of nuclear pores by more than 60%. That decrease protected them from the consequences of stress, but also impaired their ability to regenerate. “These findings are an important advance in fundamental understanding of how the heart develops with age and how it has evolved to cope with stress,” senior author Bernhard Kühn, professor of pediatrics and director of the Pediatric Institute for Heart Regeneration and Therapeutics at the University of Pittsburgh School of Medicine, said in a press release. Kühn and his colleagues published those findings in the Oct. 24, 2022, issue of Developmental Cell. Read More
Based on an analysis of critical transcription factors, researchers have stratified rheumatoid arthritis (RA) into two subtypes where gene expression was driven by RAR-α or TGF-β, respectively. The findings, published in Nature Communications on Oct. 20, 2022, by researchers from the University of California, San Diego, give new insights into factors that affect the treatment response in RA, and could point to novel treatment strategies. Read More
Researchers from Qualigen Therapeutics Inc. and University of Louisville presented the discovery and preclinical evaluation of a novel pan-RAS inhibitor... Read More
Revelation Biosciences Inc. announced positive results for REVTx-300 in a preclinical model of acute kidney injury (AKI), a type of chronic kidney disease (CKD). Read More
Protagonist Therapeutics Inc. has disclosed hepcidin mimetic conjugates acting as solute carrier family 40 member 1 (SLC40A1, ferroportin) ligands with extended half-life and stability. Read More
Blueprint Medicines Corp. has synthesized new diazepanone-fused pyrimidines acting as epidermal growth factor receptor (EGFR) (mutant) and/or HER2 (mutant) inhibitors reported to be useful for the treatment of cancer, atherosclerosis, eczema and psoriasis. Read More
Cellevolve Bio Inc. announced that the FDA has cleared its IND application for CE-VST01-JC, an allogeneic, off-the-shelf, JC-specific T-cell therapy (JC-VST) targeting JC polyoma virus (JCV), being studied for the treatment of progressive multifocal leukoencephalopathy (PML). Read More
Nimbus Saturn Inc. has presented mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1) inhibitors reported to be useful for the treatment of cancer and viral infections. Read More
Acerand Therapeutics (USA) Ltd. has discovered new son of sevenless homologue 1 (SOS1)/GTPase KRAS (G12D mutant) interaction inhibitors reported to be useful for the treatment of cancer. Read More
Ono Pharmaceutical Co. Ltd. has disclosed monoacylglycerol lipase ABHD6 inhibitors reported to be useful for the treatment of cancer, pain, neurological, inflammatory, autoimmune and metabolic diseases. Read More
